MedTrace Logo

Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia

NCT02054702 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2015-12-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia

Conditions

Interventions

DRUG

Brexpiprazole

Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally

DRUG

Aripiprazole

Up to 20 mg/day, once daily dose, tablets, orally

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    lead INDUSTRY

Principal Investigators

  • Junichi Hashimoto, PhD · Otsuka Pharmaceutical Co., Ltd Japan (OPCJ)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-06-30
Completion
2014-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02054702 on ClinicalTrials.gov